News | Brachytherapy Systems, Women's Healthcare | August 30, 2017

China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer

Approval finalizes availability of complete suite of Xoft System products in China

China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer

August 30, 2017 — iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food & Drug Administration (CFDA) for the treatment of early-stage breast cancer. The Xoft Axxent balloon applicators are a key component of the Xoft Axxent Electronic Brachytherapy (eBx) System, which is used to perform intraoperative radiation therapy (IORT) in early-stage breast cancer patients who meet specific selection criteria.

With this CFDA approval, the complete suite of Xoft System products is now available to clinicians and patients in China.

IORT with the Xoft System allows radiation oncologists and breast surgeons to work together to deliver a full course of radiation to the tumor site at the time of lumpectomy. The balloon applicator is used to deliver a single, precise dose of radiation to the lumpectomy cavity, directly targeting cancer cells while minimizing exposure to healthy surrounding tissue. In the procedure, the Xoft System’s miniaturized X-ray source is inserted into the balloon applicator, providing a channel to deliver high-dose rate, low-energy radiation treatment. The balloon applicator is available in multiple sizes and shapes, can be filled with different volumes of saline to best fit the contour of the surgical cavity, and allows delivery of a more conformal radiation dose.

“The Xoft Axxent balloon applicators offer an attractive option for physicians and patients who desire improved flexibility, precision and personalization in the targeted treatment of early-stage breast cancer,” said Liu Yu, COO of Chindex Medical Limited, the distributor of iCAD’s Xoft System in China. “We are pleased to continue working with iCAD in offering our customers access to the most advanced cancer treatments, including the complete portfolio of Xoft System products, in the years ahead.”

The Xoft System is U.S. Food and Drug Administration (FDA)-cleared for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

For more information: www.xoftinc.com

Related Content

Videos | Image Guided Radiation Therapy (IGRT) | October 15, 2018
Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute, describes the benefits the departm
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
"Where's My Mammogram?" Campaign Helps Women Own Breast Health Records
News | Breast Imaging | October 10, 2018
October 10, 2018 — Mammosphere launched “Where’s My Mammogram?,” a public service campaign to help women obtain copie
DenseBreast-info.org Launches European Expansion
News | Breast Density | October 10, 2018
DenseBreast-info.org (DB-I) announced the launch of its international expansion for European medical providers. The...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
ASTRO 2018 Radiation Therapy Clinical Trials
Feature | ASTRO | October 08, 2018
October 8, 2018 — The American Society for Radiation Oncology (ASTRO) announced the 10 top-rated clinical studies tha
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
X-ray Mammography Adoption to Skyrocket for Breast Cancer Detection
News | Mammography | October 08, 2018
Highly populated countries have traditionally been slow adopters of non-conventional business models, but a new Frost...
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...